nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2E1—Parkinson's disease	0.462	0.577	CbGaD
Dexmedetomidine—CYP2D6—Parkinson's disease	0.339	0.423	CbGaD
Dexmedetomidine—SLC6A2—locus ceruleus—Parkinson's disease	0.00822	0.153	CbGeAlD
Dexmedetomidine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.0065	0.121	CbGeAlD
Dexmedetomidine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00437	0.0811	CbGeAlD
Dexmedetomidine—SLC6A2—nerve—Parkinson's disease	0.00246	0.0456	CbGeAlD
Dexmedetomidine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00223	0.0414	CbGeAlD
Dexmedetomidine—ADRA1D—forebrain—Parkinson's disease	0.00165	0.0306	CbGeAlD
Dexmedetomidine—SLC6A2—brainstem—Parkinson's disease	0.00105	0.0196	CbGeAlD
Dexmedetomidine—SLC6A2—forebrain—Parkinson's disease	0.00102	0.0189	CbGeAlD
Dexmedetomidine—CYP2D6—hindbrain—Parkinson's disease	0.00101	0.0187	CbGeAlD
Dexmedetomidine—ADRA1B—head—Parkinson's disease	0.000964	0.0179	CbGeAlD
Dexmedetomidine—ADRA1D—head—Parkinson's disease	0.000943	0.0175	CbGeAlD
Dexmedetomidine—ADRA1B—nervous system—Parkinson's disease	0.000914	0.017	CbGeAlD
Dexmedetomidine—ADRA1D—nervous system—Parkinson's disease	0.000894	0.0166	CbGeAlD
Dexmedetomidine—ADRA1B—central nervous system—Parkinson's disease	0.00088	0.0164	CbGeAlD
Dexmedetomidine—ADRA1D—central nervous system—Parkinson's disease	0.000861	0.016	CbGeAlD
Dexmedetomidine—SLC6A2—medulla oblongata—Parkinson's disease	0.000735	0.0137	CbGeAlD
Dexmedetomidine—ADRA2A—forebrain—Parkinson's disease	0.000719	0.0134	CbGeAlD
Dexmedetomidine—ADRA1B—brain—Parkinson's disease	0.000699	0.013	CbGeAlD
Dexmedetomidine—ADRA1D—brain—Parkinson's disease	0.000683	0.0127	CbGeAlD
Dexmedetomidine—ADRA2C—medulla oblongata—Parkinson's disease	0.000651	0.0121	CbGeAlD
Dexmedetomidine—ADRA2C—midbrain—Parkinson's disease	0.000595	0.0111	CbGeAlD
Dexmedetomidine—CYP2E1—cardiovascular system—Parkinson's disease	0.000595	0.0111	CbGeAlD
Dexmedetomidine—SLC6A2—head—Parkinson's disease	0.000583	0.0108	CbGeAlD
Dexmedetomidine—ADRA2C—spinal cord—Parkinson's disease	0.000581	0.0108	CbGeAlD
Dexmedetomidine—CYP2D6—brainstem—Parkinson's disease	0.000577	0.0107	CbGeAlD
Dexmedetomidine—CYP2D6—forebrain—Parkinson's disease	0.000557	0.0104	CbGeAlD
Dexmedetomidine—SLC6A2—nervous system—Parkinson's disease	0.000552	0.0103	CbGeAlD
Dexmedetomidine—SLC6A2—central nervous system—Parkinson's disease	0.000532	0.00988	CbGeAlD
Dexmedetomidine—ADRA2A—medulla oblongata—Parkinson's disease	0.00052	0.00966	CbGeAlD
Dexmedetomidine—ADRA2C—head—Parkinson's disease	0.000516	0.00959	CbGeAlD
Dexmedetomidine—CYP2E1—medulla oblongata—Parkinson's disease	0.000508	0.00945	CbGeAlD
Dexmedetomidine—ADRA2C—nervous system—Parkinson's disease	0.000489	0.00909	CbGeAlD
Dexmedetomidine—ADRA2A—midbrain—Parkinson's disease	0.000475	0.00883	CbGeAlD
Dexmedetomidine—ADRA2C—central nervous system—Parkinson's disease	0.000471	0.00875	CbGeAlD
Dexmedetomidine—ADRA2A—spinal cord—Parkinson's disease	0.000463	0.00861	CbGeAlD
Dexmedetomidine—ADRA2C—cerebellum—Parkinson's disease	0.00046	0.00856	CbGeAlD
Dexmedetomidine—CYP2E1—spinal cord—Parkinson's disease	0.000453	0.00842	CbGeAlD
Dexmedetomidine—CYP1A1—head—Parkinson's disease	0.000442	0.00821	CbGeAlD
Dexmedetomidine—SLC6A2—brain—Parkinson's disease	0.000422	0.00785	CbGeAlD
Dexmedetomidine—CYP1A1—nervous system—Parkinson's disease	0.000419	0.00778	CbGeAlD
Dexmedetomidine—ADRA2A—head—Parkinson's disease	0.000412	0.00765	CbGeAlD
Dexmedetomidine—CYP1A1—central nervous system—Parkinson's disease	0.000403	0.00749	CbGeAlD
Dexmedetomidine—CYP2E1—head—Parkinson's disease	0.000403	0.00749	CbGeAlD
Dexmedetomidine—ADRA2A—nervous system—Parkinson's disease	0.00039	0.00726	CbGeAlD
Dexmedetomidine—CYP2E1—nervous system—Parkinson's disease	0.000382	0.0071	CbGeAlD
Dexmedetomidine—ADRA2A—central nervous system—Parkinson's disease	0.000376	0.00699	CbGeAlD
Dexmedetomidine—ADRA2C—brain—Parkinson's disease	0.000374	0.00695	CbGeAlD
Dexmedetomidine—CYP2E1—central nervous system—Parkinson's disease	0.000368	0.00683	CbGeAlD
Dexmedetomidine—ADRA2A—cerebellum—Parkinson's disease	0.000367	0.00683	CbGeAlD
Dexmedetomidine—CYP2E1—cerebellum—Parkinson's disease	0.000359	0.00668	CbGeAlD
Dexmedetomidine—CYP1A1—brain—Parkinson's disease	0.00032	0.00595	CbGeAlD
Dexmedetomidine—CYP2D6—head—Parkinson's disease	0.000319	0.00593	CbGeAlD
Dexmedetomidine—CYP2D6—nervous system—Parkinson's disease	0.000302	0.00562	CbGeAlD
Dexmedetomidine—ADRA2A—brain—Parkinson's disease	0.000298	0.00555	CbGeAlD
Dexmedetomidine—CYP2E1—brain—Parkinson's disease	0.000292	0.00543	CbGeAlD
Dexmedetomidine—CYP2D6—central nervous system—Parkinson's disease	0.000291	0.00541	CbGeAlD
Dexmedetomidine—CYP2D6—cerebellum—Parkinson's disease	0.000285	0.00529	CbGeAlD
Dexmedetomidine—CYP2D6—brain—Parkinson's disease	0.000231	0.0043	CbGeAlD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—HTR7—Parkinson's disease	3.14e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PLA2G6—Parkinson's disease	3.13e-05	0.000216	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGF20—Parkinson's disease	3.12e-05	0.000216	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GCH1—Parkinson's disease	3.1e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—EDN1—Parkinson's disease	3.1e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MAOB—Parkinson's disease	3.09e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—INSR—Parkinson's disease	3.09e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—EDN1—Parkinson's disease	3.05e-05	0.000211	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ADORA2A—Parkinson's disease	3.02e-05	0.000209	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EDN1—Parkinson's disease	3.01e-05	0.000208	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTA4—Parkinson's disease	3.01e-05	0.000208	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	2.97e-05	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—ADRBK1—Parkinson's disease	2.94e-05	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGB—Parkinson's disease	2.92e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HTR2A—Parkinson's disease	2.92e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGF20—Parkinson's disease	2.91e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HTR1A—Parkinson's disease	2.91e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDYN—Parkinson's disease	2.9e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	2.9e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—HTR2A—Parkinson's disease	2.9e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PLA2G6—Parkinson's disease	2.87e-05	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGF20—Parkinson's disease	2.87e-05	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TAC1—Parkinson's disease	2.86e-05	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—DRD2—Parkinson's disease	2.85e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HTR7—Parkinson's disease	2.85e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MAOB—Parkinson's disease	2.84e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP2D6—Parkinson's disease	2.83e-05	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ADORA2A—Parkinson's disease	2.83e-05	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EDN1—Parkinson's disease	2.81e-05	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DRD1—Parkinson's disease	2.81e-05	0.000194	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	2.8e-05	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—INSR—Parkinson's disease	2.79e-05	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ADORA2A—Parkinson's disease	2.78e-05	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CTGF—Parkinson's disease	2.78e-05	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EDN1—Parkinson's disease	2.77e-05	0.000192	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GBA—Parkinson's disease	2.77e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—FBP1—Parkinson's disease	2.77e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—DBH—Parkinson's disease	2.77e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GFAP—Parkinson's disease	2.73e-05	0.000189	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DRD3—Parkinson's disease	2.72e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—HTR2A—Parkinson's disease	2.71e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PLA2G6—Parkinson's disease	2.71e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GRM5—Parkinson's disease	2.7e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MAOB—Parkinson's disease	2.68e-05	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—HTR2A—Parkinson's disease	2.66e-05	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGB—Parkinson's disease	2.64e-05	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HTR2A—Parkinson's disease	2.63e-05	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HTR1A—Parkinson's disease	2.62e-05	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—INSR—Parkinson's disease	2.61e-05	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP2E1—Parkinson's disease	2.59e-05	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TAC1—Parkinson's disease	2.58e-05	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—INSR—Parkinson's disease	2.57e-05	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NQO1—Parkinson's disease	2.56e-05	0.000177	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.55e-05	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ADRBK1—Parkinson's disease	2.54e-05	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DRD1—Parkinson's disease	2.53e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—TH—Parkinson's disease	2.52e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	2.51e-05	0.000174	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGB—Parkinson's disease	2.46e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DRD2—Parkinson's disease	2.46e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HTR7—Parkinson's disease	2.46e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HTR2A—Parkinson's disease	2.46e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DRD3—Parkinson's disease	2.46e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HTR1A—Parkinson's disease	2.45e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGB—Parkinson's disease	2.43e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYCS—Parkinson's disease	2.42e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HTR2A—Parkinson's disease	2.42e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TAC1—Parkinson's disease	2.41e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HTR1A—Parkinson's disease	2.41e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—DDC—Parkinson's disease	2.4e-05	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TAC1—Parkinson's disease	2.38e-05	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DRD1—Parkinson's disease	2.37e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	2.37e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DRD1—Parkinson's disease	2.33e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	2.3e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	2.3e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DRD3—Parkinson's disease	2.29e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ADRBK1—Parkinson's disease	2.29e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	2.28e-05	0.000158	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	2.26e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CTGF—Parkinson's disease	2.26e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DRD3—Parkinson's disease	2.26e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DRD2—Parkinson's disease	2.22e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HTR7—Parkinson's disease	2.22e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	2.2e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—COMT—Parkinson's disease	2.15e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ADRBK1—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTP1—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MAOA—Parkinson's disease	2.13e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	2.12e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP2D6—Parkinson's disease	2.11e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ADRBK1—Parkinson's disease	2.11e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—HMOX1—Parkinson's disease	2.11e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	2.1e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NQO1—Parkinson's disease	2.08e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HTR7—Parkinson's disease	2.07e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DRD2—Parkinson's disease	2.07e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CTGF—Parkinson's disease	2.07e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF2—Parkinson's disease	2.06e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—TH—Parkinson's disease	2.05e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DRD2—Parkinson's disease	2.04e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HTR7—Parkinson's disease	2.04e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	2.04e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—DDC—Parkinson's disease	2.03e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ABCB1—Parkinson's disease	2.02e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MAOB—Parkinson's disease	2.02e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	2e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	2e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1R—Parkinson's disease	1.99e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	1.99e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2D6—Parkinson's disease	1.99e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EDN1—Parkinson's disease	1.97e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYCS—Parkinson's disease	1.97e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTM1—Parkinson's disease	1.96e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	1.96e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CTGF—Parkinson's disease	1.95e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	1.92e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTA4—Parkinson's disease	1.92e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NQO1—Parkinson's disease	1.91e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.89e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—TH—Parkinson's disease	1.88e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GPX1—Parkinson's disease	1.88e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	1.86e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF2—Parkinson's disease	1.86e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2E1—Parkinson's disease	1.82e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NGF—Parkinson's disease	1.81e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYCS—Parkinson's disease	1.81e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NQO1—Parkinson's disease	1.8e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1R—Parkinson's disease	1.8e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EDN1—Parkinson's disease	1.78e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—TH—Parkinson's disease	1.77e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—COMT—Parkinson's disease	1.74e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	1.74e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF2—Parkinson's disease	1.74e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	1.73e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MTHFR—Parkinson's disease	1.73e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MAOA—Parkinson's disease	1.73e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	1.73e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HTR2A—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	1.71e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF2—Parkinson's disease	1.71e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MAOB—Parkinson's disease	1.71e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYCS—Parkinson's disease	1.7e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	1.68e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	1.68e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1R—Parkinson's disease	1.68e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EDN1—Parkinson's disease	1.66e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1R—Parkinson's disease	1.65e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	1.64e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EDN1—Parkinson's disease	1.63e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NGF—Parkinson's disease	1.63e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.63e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—APOE—Parkinson's disease	1.61e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—APOE—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—COMT—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	1.59e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTP1—Parkinson's disease	1.59e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MAOA—Parkinson's disease	1.59e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—HMOX1—Parkinson's disease	1.57e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HTR2A—Parkinson's disease	1.56e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GPX1—Parkinson's disease	1.53e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NGF—Parkinson's disease	1.53e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—COMT—Parkinson's disease	1.51e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ABCB1—Parkinson's disease	1.51e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTP1—Parkinson's disease	1.5e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NGF—Parkinson's disease	1.5e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MAOA—Parkinson's disease	1.5e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—HMOX1—Parkinson's disease	1.48e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CTGF—Parkinson's disease	1.47e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—Parkinson's disease	1.46e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HTR2A—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APOE—Parkinson's disease	1.45e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HTR2A—Parkinson's disease	1.43e-05	9.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ABCB1—Parkinson's disease	1.42e-05	9.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	1.41e-05	9.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	1.41e-05	9.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GPX1—Parkinson's disease	1.4e-05	9.71e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—Parkinson's disease	1.38e-05	9.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—INS—Parkinson's disease	1.38e-05	9.55e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.37e-05	9.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—INS—Parkinson's disease	1.37e-05	9.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	1.36e-05	9.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.36e-05	9.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APOE—Parkinson's disease	1.35e-05	9.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	1.35e-05	9.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TH—Parkinson's disease	1.34e-05	9.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APOE—Parkinson's disease	1.33e-05	9.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GPX1—Parkinson's disease	1.32e-05	9.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APOE—Parkinson's disease	1.31e-05	9.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—Parkinson's disease	1.29e-05	8.96e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.28e-05	8.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	1.27e-05	8.79e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CTGF—Parkinson's disease	1.25e-05	8.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	1.24e-05	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—INS—Parkinson's disease	1.24e-05	8.55e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—Parkinson's disease	1.22e-05	8.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APOE—Parkinson's disease	1.2e-05	8.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	1.18e-05	8.17e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	1.16e-05	8.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—INS—Parkinson's disease	1.15e-05	7.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NQO1—Parkinson's disease	1.15e-05	7.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—COMT—Parkinson's disease	1.14e-05	7.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOE—Parkinson's disease	1.14e-05	7.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—INS—Parkinson's disease	1.14e-05	7.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TH—Parkinson's disease	1.13e-05	7.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.13e-05	7.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.13e-05	7.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—INS—Parkinson's disease	1.12e-05	7.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.11e-05	7.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	1.1e-05	7.59e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYCS—Parkinson's disease	1.09e-05	7.52e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.07e-05	7.41e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.04e-05	7.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—INS—Parkinson's disease	1.03e-05	7.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—Parkinson's disease	1.02e-05	7.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—Parkinson's disease	1.01e-05	7.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GPX1—Parkinson's disease	9.95e-06	6.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—INS—Parkinson's disease	9.7e-06	6.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—COMT—Parkinson's disease	9.62e-06	6.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—Parkinson's disease	9.58e-06	6.63e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MAOA—Parkinson's disease	9.55e-06	6.61e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—Parkinson's disease	9.45e-06	6.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	9.37e-06	6.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK8—Parkinson's disease	9.36e-06	6.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—Parkinson's disease	9.2e-06	6.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	9.18e-06	6.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—Parkinson's disease	9.14e-06	6.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—Parkinson's disease	9.07e-06	6.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—Parkinson's disease	8.8e-06	6.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—Parkinson's disease	8.59e-06	5.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOE—Parkinson's disease	8.55e-06	5.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—Parkinson's disease	8.53e-06	5.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—Parkinson's disease	8.45e-06	5.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK8—Parkinson's disease	8.45e-06	5.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GPX1—Parkinson's disease	8.43e-06	5.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—Parkinson's disease	8.4e-06	5.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK8—Parkinson's disease	7.89e-06	5.46e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—Parkinson's disease	7.78e-06	5.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK8—Parkinson's disease	7.77e-06	5.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—INS—Parkinson's disease	7.3e-06	5.06e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOE—Parkinson's disease	7.24e-06	5.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	6.98e-06	4.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	6.93e-06	4.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	6.41e-06	4.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—INS—Parkinson's disease	6.19e-06	4.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—Parkinson's disease	5.98e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—Parkinson's disease	5.4e-06	3.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—Parkinson's disease	5.04e-06	3.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—Parkinson's disease	4.96e-06	3.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	4.09e-06	2.83e-05	CbGpPWpGaD
